Sandrock Alfred 4
4 · Voyager Therapeutics, Inc. · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Voyager (VYGR) CEO Alfred Sandrock Sells 11,511 Shares
What Happened Alfred Sandrock, President and CEO of Voyager Therapeutics, sold 11,511 shares of Voyager common stock on April 2, 2026. The weighted-average sale price was $3.87 per share, for gross proceeds of about $44,548. The sale was made pursuant to a durable automatic sell instruction to satisfy tax withholding in connection with restricted stock units that vested on April 1, 2026 — not a discretionary trade by the reporting person.
Key Details
- Transaction date: April 2, 2026 (Form filed April 3, 2026) — filing appears timely.
- Price: weighted average $3.87; execution prices ranged from $3.81 to $3.95 across multiple trades.
- Shares sold: 11,511; gross proceeds ≈ $44,548.
- Reason/footnote: sell-to-cover under an automatic instruction adopted May 12, 2025, to satisfy tax withholding for RSU vesting (footnote F1). Reporting person states the sales were not discretionary.
- Footnote F2: price shown is a weighted average; the filer will provide per-trade breakdown on request.
- Shares owned after the transaction: not disclosed in the information provided in this filing.
Context This was a routine sell-to-cover tied to RSU vesting (tax-withholding), a common administrative sale that generally does not signal a voluntary decision to reduce exposure. For retail investors, outright purchases by insiders are typically more informative about insider sentiment; tax-related sales are usually procedural.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-04-02$3.87/sh−11,511$44,548→ 472,549 total
Footnotes (2)
- [F1]Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.